|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.10.25 - 13:03
|
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to...
|
|
|
|
|
|
|
15.10.25 - 10:00
|
Astria Therapeutics: Übernahme beschert sharedealsPlus +200% nach Tipp (Sharedeals)
|
|
|
Die nächste Übernahme, die nächste Party für Mitglieder von sharedealsPlus: Mit der Aktie von Astria Therapeutics feiert die Community einen Verdreifacher in nur sechs Monaten. Mit einem Paukenschlag stärkt BioCryst Pharmaceuticals seine Position im lukrativen Markt für seltene Erkrankungen: Das US-Biotechunternehmen kündigte die Übernahme von Astria Therapeutics an. Die Transaktion, bestehend aus Bargeld und Aktien, […]
The post Astria Therapeutics: Übernahme beschert sharedealsPlus +200% nach Tipp first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
03.10.25 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees stock options to purchase an aggregate of 115,000 shares, and restricted stock units (RSUs) covering an aggregate of 91,450 shares, of BioCryst common stock. The options and RSUs were granted as of October 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
03.09.25 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 71,400 shares, of BioCryst common stock. The options and RSUs were granted as of September 2, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
21.08.25 - 13:03
|
BioCryst to Present at Upcoming Investor Conference (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
